Staar Surgical Co (STAA) reports Q1 2026 results: $93.5M sales, $5.2M net income, and positive EBITDA. Discover key growth insights.

Key Takeaways

• Net sales reached $93.5 million, up 119.6% year-over-year, driven by strong performance in China and the U.S.
• Adjusted EBITDA turned positive at $24.4 million, compared to a loss of $26.3 million in Q1 2025.
• Net income increased to $5.2 million or $0.10 per share, reversing a loss of $54.2 million or $1.10 per share from the previous year.
• Gross profit margin improved to 73.6%, up from 65.8% in Q1 2025, reflecting operational efficiencies.
• The company surpassed 4 million ICLs sold globally, showcasing robust demand for its products.

Financial Performance

Staar Surgical Co reported impressive results for Q1 2026, marking a significant recovery from the challenges faced in 2025. The company achieved net sales of $93.5 million, demonstrating a remarkable 119.6% increase compared to the same period last year. This growth was primarily fueled by strong sales in China, which contributed $47.4 million, along with a record quarter in the U.S. exceeding $6 million.

Adjusted EBITDA showed a significant turnaround, reaching $24.4 million, compared to a loss of $26.3 million in Q1 2025. The gross profit margin also improved, climbing to 73.6% from 65.8% last year, driven by operational efficiencies and reduced costs of goods sold. The decline in total operating expenses to $60.9 million, down from $85.4 million, reflects the company's commitment to disciplined spending.

Strategic Initiatives

During the quarter, Staar Surgical made substantial progress on various strategic fronts. Key highlights include:

• Launch of EVO plus ICL in China: Staar began shipping significant volumes of its new product, which is expected to enhance its market presence.
• Normalized inventory levels in China: This aligns with contractual targets and allowed for growth without increasing excess stock.
• Manufacturing advancements: The company’s facility in Neuchâtel, Switzerland, is on track to supply all EVO and EVO plus lenses to China, mitigating prior tariff concerns.
• ERP system rollout: The implementation of the new Oracle ERP system is proceeding with minimal disruption, aimed at improving operational efficiency.

These initiatives are crucial for sustaining momentum in revenue growth and expanding profitability, reinforcing the company’s long-term vision.

Future Outlook

Looking ahead, management remains optimistic about the company's growth trajectory. While they have not provided specific guidance for Q2, they indicated that they expect to continue benefiting from strong demand for lens-based refractive surgeries, particularly as the market stabilizes in China.

Management expressed cautious optimism regarding the remainder of the year, with a potential for continued growth in the U.S. market, especially with the recent FDA approval expanding the EVO ICL indication for patients aged 45 to 60. This regulatory development is anticipated to broaden the addressable market significantly.

Despite geopolitical and macroeconomic uncertainties impacting other regions, management is focused on disciplined capital allocation, prioritizing markets with the highest growth potential. The company aims to build on its recent performance while carefully monitoring external factors.

Warren Faust, Interim Co-CEO, emphasized the importance of maintaining operational discipline and leveraging the company’s differentiated technology to drive future growth. This commitment to innovation and efficiency positions Staar well for long-term value creation.

In summary, Staar Surgical's impressive Q1 results reflect a solid recovery and proactive management strategies that have allowed the company not only to regain profitability but also to expand its market share in a growing sector.

Overall, Staar Surgical Co appears to be on a positive trajectory, with strategic initiatives in place and a favorable outlook for the future. The company's focus on innovation and operational efficiency will be critical as it navigates the evolving landscape of the refractive surgery market.

This analysis is based on public earnings call materials and is not investment advice.